Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Flare Therapeutics raises $85M in Series C financing led by Third Rock Ventures and Nextech Invest to advance its ARON degrader program.

PRIVATEJun 30, 2026•about 1 month ago

Amount Raised

$85 Million

Round Type

Series C

CambridgeBiotechnologyHealth CareTherapeutics

Investors

Eventide Asset ManagementAgent CapitalNovartisEli Lilly And CompanyCasdin CapitalInvusGordon Md Global Investments® LpBoxer CapitalPfizer VenturesNextech InvestThird Rock Ventures

Description

Flare Therapeutics closed an $85 million Series C financing led by existing investors, including Third Rock Ventures and Nextech Invest. The funding will be used to advance its FX-111 program and for general corporate purposes. Additionally, Anna Protopapas has been appointed as CEO to lead the company through its next growth phase focused on prostate cancer. The financing also includes participation from notable investors such as Pfizer Ventures and Novartis.

Company Information

Company

Flare Therapeutics

Location

Cambridge, Massachusetts, United States

About

Flare Therapeutics is a biotechnology company exclusively focused on drugging transcription factors (TFs) to fully unlock the therapeutic potential of this previously elusive target class. Flare Therapeutics' integrated discovery engine converges rich genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating TFs of high therapeutic potential. Flare Therapeutics' proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to Flare Therapeutics. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that is currently in a Phase I study. For more information, please visit www.flaretx.com and follow us on LinkedIn.

Related People

Suggested for you
1 contact
Verified contactsNo contacts on file at Flare Therapeutics yet.
Predictive Intelligence
Strategic

ML-powered predictions for Flare Therapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.